Published in Women's Health Weekly, December 21st, 2006
Sosei acquired the exclusive distribution rights to the product in Japan from Laboratoire HRA Pharma; it is currently approved and marketed in over 50 countries.
The clinical study is a randomized, double blind, placebo-controlled trial designed to evaluate the safety and pharmacokinetics of SOH-075 in healthy Japanese adult female volunteers. A total of 33 volunteers in three cohorts will be enrolled at a single study center.
NorLevo is an oral...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly